Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Convertible Debt: 2021-2022

  • China Pharma Holdings' Convertible Debt was N/A to $4.8 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2021, which is N/A change from last year.
  • Per China Pharma Holdings' latest filing, its Convertible Debt stood at $4.8 million for Q2 2022, which was down 4.04% from $5.0 million recorded in Q1 2022.
  • China Pharma Holdings' 5-year Convertible Debt high stood at $5.2 million for Q4 2021, and its period low was $4.8 million during Q2 2022.
  • Moreover, its 2-year median value for Convertible Debt was $5.0 million (2022), whereas its average is $5.0 million.